title: Recalcitrant nasal polyposis: achievement of total remission following treatment with omalizumab.
authors.affiliation: Department of Pulmonology - Respiratory Pathophysiology, AOU San Luigi Gonzaga, Orbassano, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Guglielmo
authors.forename: C
authors.initials: C
authors.lastname: Gulotta
authors.forename: F
authors.initials: F
authors.lastname: Mancini
authors.forename: M
authors.initials: M
authors.lastname: Sacchi
authors.forename: F
authors.initials: F
authors.lastname: Tarantini
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000485:Allergens / Q000276:immunology; D000818:Animals; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000150:complications / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D002908:Chronic Disease; D006261:Headache; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D008297:Male; D008875:Middle Aged; D015508:Nasal Obstruction; D009298:Nasal Polyps / Q000150:complications / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D000857:Olfaction Disorders; D000069444:Omalizumab; D011058:Pollen / Q000276:immunology; D039981:Pyroglyphidae / Q000276:immunology; D012074:Remission Induction; D012220:Rhinitis / Q000150:complications / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D055502:Secondary Prevention; D012852:Sinusitis / Q000150:complications / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*
chemical_list: D000305:Adrenal Cortex Hormones; D000485:Allergens; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E